Different effects of surfactant and inhaled nitric oxide in modulation of inflammatory injury in ventilated piglet lungs

Pulm Pharmacol Ther. 2005;18(4):303-13. doi: 10.1016/j.pupt.2005.01.005.

Abstract

Septic acute lung injury (ALI) causes high morbidity and mortality in intensive care service as a result of biotrauma and dysfunction in the lungs and other organ systems. We hypothesized that surfactant and/or inhaled nitric oxide (iNO) may have different effects in modulation of inflammatory injury in septic ALI. Twenty-four healthy, 6-9 kg piglets were anesthetized, and intraperitoneally injected with Escherichia coli, followed by a low tidal volume ventilation until sepsis and ALI developed within 4-6 h. They were then randomly treated in groups (n=6 each) as: control (C), inhaled NO at 10 ppm (NO), surfactant at 100mg/kg (Surf), or both surfactant and iNO (SNO). A normal control group (N) was sham-injected and similarly ventilated. Over the 24 h of treatment period, both Surf, and SNO groups had significantly improved PaO2/FiO2, dynamic compliance and resistance of respiratory system. At 24h, the best alveolar aeration and least protein leakage, the lowest wet-to-dry lung weight ratio and lung injury score were found in SNO. Activity of nuclear factor kappa B (NF-kappaB) and myeloperoxidase, interleukin 8 mRNA expression and melondialdehyde were significantly increased, and IL-10 mRNA decreased, in lung tissue of the C group, but were significantly altered in the SNO group, and moderately altered in either NO or Surf group. We conclude that the effects of lung protection by surfactant and/or iNO in this model may be different in modulation of inflammatory cytokine mRNA expression and activity of NF-kappaB, and iNO did not have adverse effects.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Administration, Inhalation
  • Analysis of Variance
  • Animals
  • Bronchoalveolar Lavage Fluid / chemistry
  • Bronchoalveolar Lavage Fluid / cytology
  • Electrophoretic Mobility Shift Assay
  • Escherichia coli Infections / complications
  • Fibroblast Growth Factor 7 / genetics
  • Interleukin-10 / genetics
  • Interleukin-8 / genetics
  • Lung / drug effects
  • Lung / metabolism
  • Lung / pathology
  • Male
  • Malondialdehyde / metabolism
  • Methemoglobin / metabolism
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nitrates / blood
  • Nitric Oxide / administration & dosage
  • Nitric Oxide / pharmacology*
  • Nitrites / blood
  • Oligonucleotide Probes / metabolism
  • Peroxidase / metabolism
  • Pneumonia / etiology
  • Pneumonia / metabolism
  • Pneumonia / prevention & control*
  • Protein Binding / drug effects
  • Pulmonary Surfactants / pharmacology*
  • Pulmonary Ventilation
  • RNA, Messenger / chemistry
  • RNA, Messenger / genetics
  • Respiratory Insufficiency / etiology
  • Respiratory Insufficiency / metabolism
  • Respiratory Insufficiency / prevention & control*
  • Swine

Substances

  • Interleukin-8
  • NF-kappa B
  • Nitrates
  • Nitrites
  • Oligonucleotide Probes
  • Pulmonary Surfactants
  • RNA, Messenger
  • Fibroblast Growth Factor 7
  • Interleukin-10
  • Nitric Oxide
  • Malondialdehyde
  • Methemoglobin
  • Peroxidase